In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

William Looney

Executive Editor

New York, NY
Advertisement
Set Alert for Articles By William Looney

Latest From William Looney

Cancer Vaccines: Is There A Future Beyond Trial And Error?

Strong foundational research in immunology and some promising early phase trial results have so far failed to expedite the validation of vaccines to treat cancer. In Vivo examines biopharma’s enduring optimism about the future of cancer vaccinology, including a closer look at one company’s platform to tackle the incurable malignancies that beset the mother of all organs: the human brain.

Innovation ImmunoOncology

Bayer’s US Playbook: The Smart Way To Top-Line Growth

The hotly contested US market is central to Bayer’s aspirations to become a global innovation player in pharmaceuticals, especially in key growth segments like oncology. A little more than one year in, Bayer Pharmaceuticals Americas President Dr. Carsten Brunn reflects on his unit’s progress.

Leadership Growth

US FDA’s Khozin On Defining Big Data, Safety Signaling, And The Patient Experience in Cancer

The challenge for users of big data "is to develop the human organizational and technical capacity to turn the 'big”' into the 'smart,' through applied analytics to personalize therapies around the distinctive disease characteristics of each patient." Khozin says.
Clinical Trials Digital Health

Big Data And The FDA: To Mine The Value, First Mind The Gaps

INFORMED is a new initiative at the FDA to incubate new ideas in applying big data to boost the scientific, economic and social returns from the regulation of drugs and medical devices, with a particular focus on cancer.

Clinical Trials Digital Health

Pfizer’s Reference Point on Trial Innovation: Ask the Patient

Pfizer, an early leader in putting patients forward in the conduct of clinical trials, is continuing to test ways to move beyond process improvements to more ambitious initiatives at the front end of technology innovation.

Clinical Trials Research & Development

Procurement In Practice: For Roivant Sciences, Speed Is The VANTage Point

Roivant has a unique business model of a connected family of operationally independent companies – known as “Vants” – each with a mission to develop and commercialize new therapies for patients with unmet medical needs. In an interview with Roivant's Kris Ungvarsky, In Vivo takes a closer look at how this affect sourcing and procurement.

Business Strategies Growth
See All
Advertisement
UsernamePublicRestriction

Register